Approval · Notice of Compliance 32293 · 2023
MYLAN-ELETRIPTAN: Notice of Compliance 32293
Issued December 5, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32293
- Date
- December 5, 2023
- Company
- Mylan Pharmaceuticals UlcEtobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative: Change in Product Ownership. Administrative: Licensing Agreement Between Two Manufacturers
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MYLAN-ELETRIPTAN | 02342235 | Marketed |
| MYLAN-ELETRIPTAN | 02342243 | Marketed |
Medicinal ingredients
- ELETRIPTAN HYDROBROMIDE 20 MG per TAB
- ELETRIPTAN HYDROBROMIDE 40 MG per TAB